Time To Rake In Healthy Returns From PDL BioPharma, Inc. (PDLI)

PDL BioPharma, Inc. (PDLI) shares saw a recent bid of $2.27 and 1.28M shares have exchanged hands in the recent trading session, yielding a -8.10% decline over the past week. The stock price decreased -2.99% or $0.07 versus $2.34 at the end of the prior session. This change led market cap to move at $359.52M, putting the price -39.79% below the 52-week high and 17.62% above the 52-week low. The company’s stock has a normal trading capacity of 1.83M shares while the relative volume is 0.70.

To stay one step ahead we extended our research by comparing different price targets. The stock notched a 12-month high of $3.25 while $4.00 target is by far the most aggressive out of analysts who are currently evaluating the company, $0.75 higher than the next highest 52-week price estimate. The lowest 12-month price target for the shares is $2.50, which would be an increase of about 10% of its current value. The mean target of $3.25 should be compared with the price when the stock was languishing around $1.93 a share. And it remains to be seen which target price PDLI can achieve without sacrificing much as the company is holding a -27.94% fall for the past twelve months.

By historical standards, PDL BioPharma, Inc. remains a cheap stock. The company’s current price-earnings ratio amounts to 25.71 times earnings, below the average P/E ratio of 233.99 times earnings. For now, PDL BioPharma, Inc. is the toast of Wall Street as its ABR stands at 2.50 with 0 out of 2 analysts rating the stock a buy. Over the short term, some market observers may have noticed that PDL BioPharma, Inc. has a 7.90% short float with 15 days to cover. It becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume. PDL BioPharma, Inc. has far performed well this year, with the share price up 7.08% since January. Over the past 2 quarters, the stock is up 12.94%, compared with a gain of nearly 4.13% for 3 months and about -4.62% for the past 30 days.

Revenue for the quarter also did not kill consensus, coming in at $45.44M, compared to the consensus of 50.23M. Nonetheless, from here on out, earnings per share forecasts for the current quarter are $0.09. The company is expected to report EPS as high as $0.14 and as low as $0.04 per share. Similarly, full-year EPS forecasts have ranged between $0.19 and $0.22. The mean EPS estimate is $0.21. On the other side, sales forecasts for the current quarter are $56.3M. The stock is expected to report revenue as high as $66.27M and as low as $46.33M per share. Similarly, full-year sales forecasts have ranged between $182.1M and $194.58M. The mean revenue estimate is $189.04M.

Over the last 5 years, PDL BioPharma, Inc. has averaged a -6.60% YoY EPS growth rate and a -7.60% revenue growth rate. Analysts are expecting EPS growth rates to be at -81.00% this quarter and EPS estimate for next year reflect -33.85% growth rate.




Sell-side analysts also have something to say about this company. RBC Capital Mkts analysts stated on 23/02/2016 that they maintained their Sector Perform rating. RBC Capital Mkts analysts stated on 02/02/2016 that they maintained their Sector Perform rating. RBC Capital Mkts analysts stated on 05/11/2015 that they maintained their Sector Perform rating.

Leave a Reply

Your email address will not be published. Required fields are marked *